Dabrafenib and/or Trametinib Rollover Study

Clinical trial NCT03340506 · RECRUITING

Trial details

NCT number: NCT03340506
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Melanoma Non Small Cell Lung Cancer Solid Tumor Rare Cancers High Grade Glioma

Start date: 2018-01-26
Primary completion: 2032-12-28
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.